<DOC>
	<DOCNO>NCT00625378</DOCNO>
	<brief_summary>This study enable patient receive sorafenib ( Nexavar ) complete Bayer/Onyx sponsor clinical trial continue treatment . During entire course study , numerous patient treat sorafenib . Involvement study depend whether patient benefit treatment , base physician 's judgment result particular additional examination . Overall , participation study help evaluate safety efficacy treatment sorafenib .</brief_summary>
	<brief_title>Sorafenib Long Term Extension Program ( STEP )</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients , participate previous Bayer/Onyx sponsor study reach endpoint ( statistical regulatory study end ) , , opinion Investigator , expect continue overall positive benefit/risk continue treatment . Patients sign informed consent long term extension program . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation , include 30 day period last study drug dosing . The investigator advise patient achieve adequate contraception . Women childbearing potential negative pregnancy test within 7 day first dose sorafenib long term extension program . Patient receive sorafenib ( Nexavar ) monotherapy originate protocol . Patients treat sorafenib ( Nexavar ) combination chemotherapy original study , continue single agent sorafenib ( Nexavar ) discontinuation combination agent eligible . Patient receive concurrent combination sorafenib ( Nexavar ) TACE ( transarterial chemoembolization ) originate study eligible . Patients complete End Treatment assessment originate study . Every effort e make conduct End Treatment visit patient interruption sorafenib dose . Any condition unstable could jeopardize safety patient ( please refer Investigator Brochure product label safety section ) . History cardiac disease : congestive heart failure &gt; NYHA Class 2 uncontrolled hypertension Myocardial infarction ( MI ) within last 3 month Symptomatic metastatic brain meningeal tumor Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) cancer curatively treat &gt; 5 year prior study entry . Patients seizure disorder require medication ( steroid antiepileptic ) Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Any condition could jeopardise safety patient his/her compliance study Excluded therapy medication , previous concomitant : Concurrent anticancer chemotherapy , except TACE ( transarterial chemoembolization ) , within 30 day prior start study drug Concurrent immunotherapy ( include monoclonal antibody ) , within 30 day prior start study drug Concurrent hormonal therapy , except bisphosphonates , within 30 day prior start study drug Concomitant Rifampicin St John 's Wort ( Warfarin may use close monitoring . ) Radiotherapy study within 3 week start study drug . [ Palliative radiotherapy allow ] Concomitant use potent inhibitor CYP 3A4 include ketoconazole , itraconazole ritonavir . Consumption grapefruit juice also avoid .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Extension program</keyword>
</DOC>